Hypercholesterolemia in children and adolescents: focus on the familial variant
Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
I. N. Zakharova [verfasserIn] I. M. Osmanov [verfasserIn] I. I. Pshenichnikova [verfasserIn] T. M. Tvorogova [verfasserIn] I. N. Kholodova [verfasserIn] I. V. Berezhnaya [verfasserIn] E. V. Skorobogatova [verfasserIn] D. I. Kholodov [verfasserIn] T. I. Bocharova [verfasserIn] Yu. V. Koba [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Медицинский совет - Remedium Group LLC, 2019, (2021), 17, Seite 294-299 |
|---|---|
| Übergeordnetes Werk: |
year:2021 ; number:17 ; pages:294-299 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.21518/2079-701X-2021-17-294-299 |
|---|
| Katalog-ID: |
DOAJ078833868 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ078833868 | ||
| 003 | DE-627 | ||
| 005 | 20230505014319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230307s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2021-17-294-299 |2 doi | |
| 035 | |a (DE-627)DOAJ078833868 | ||
| 035 | |a (DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a I. N. Zakharova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypercholesterolemia in children and adolescents: focus on the familial variant |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. | ||
| 650 | 4 | |a hypercholesterolemia | |
| 650 | 4 | |a cascade screening | |
| 650 | 4 | |a universal screening | |
| 650 | 4 | |a targeted screening | |
| 650 | 4 | |a opportunistic screening | |
| 650 | 4 | |a lipid center | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a I. M. Osmanov |e verfasserin |4 aut | |
| 700 | 0 | |a I. I. Pshenichnikova |e verfasserin |4 aut | |
| 700 | 0 | |a T. M. Tvorogova |e verfasserin |4 aut | |
| 700 | 0 | |a I. N. Kholodova |e verfasserin |4 aut | |
| 700 | 0 | |a I. V. Berezhnaya |e verfasserin |4 aut | |
| 700 | 0 | |a E. V. Skorobogatova |e verfasserin |4 aut | |
| 700 | 0 | |a D. I. Kholodov |e verfasserin |4 aut | |
| 700 | 0 | |a T. I. Bocharova |e verfasserin |4 aut | |
| 700 | 0 | |a Yu. V. Koba |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2021), 17, Seite 294-299 |w (DE-627)1760607460 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g number:17 |g pages:294-299 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2021-17-294-299 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/6513 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2021 |e 17 |h 294-299 | ||
| author_variant |
i n z inz i m o imo i i p iip t m t tmt i n k ink i v b ivb e v s evs d i k dik t i b tib y v k yvk |
|---|---|
| matchkey_str |
article:26585790:2021----::yecoetrlmanhlrnnaoecnsouo |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.21518/2079-701X-2021-17-294-299 doi (DE-627)DOAJ078833868 (DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff DE-627 ger DE-627 rakwb rus I. N. Zakharova verfasserin aut Hypercholesterolemia in children and adolescents: focus on the familial variant 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. hypercholesterolemia cascade screening universal screening targeted screening opportunistic screening lipid center Medicine R I. M. Osmanov verfasserin aut I. I. Pshenichnikova verfasserin aut T. M. Tvorogova verfasserin aut I. N. Kholodova verfasserin aut I. V. Berezhnaya verfasserin aut E. V. Skorobogatova verfasserin aut D. I. Kholodov verfasserin aut T. I. Bocharova verfasserin aut Yu. V. Koba verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2021), 17, Seite 294-299 (DE-627)1760607460 26585790 nnns year:2021 number:17 pages:294-299 https://doi.org/10.21518/2079-701X-2021-17-294-299 kostenfrei https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff kostenfrei https://www.med-sovet.pro/jour/article/view/6513 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 17 294-299 |
| spelling |
10.21518/2079-701X-2021-17-294-299 doi (DE-627)DOAJ078833868 (DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff DE-627 ger DE-627 rakwb rus I. N. Zakharova verfasserin aut Hypercholesterolemia in children and adolescents: focus on the familial variant 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. hypercholesterolemia cascade screening universal screening targeted screening opportunistic screening lipid center Medicine R I. M. Osmanov verfasserin aut I. I. Pshenichnikova verfasserin aut T. M. Tvorogova verfasserin aut I. N. Kholodova verfasserin aut I. V. Berezhnaya verfasserin aut E. V. Skorobogatova verfasserin aut D. I. Kholodov verfasserin aut T. I. Bocharova verfasserin aut Yu. V. Koba verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2021), 17, Seite 294-299 (DE-627)1760607460 26585790 nnns year:2021 number:17 pages:294-299 https://doi.org/10.21518/2079-701X-2021-17-294-299 kostenfrei https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff kostenfrei https://www.med-sovet.pro/jour/article/view/6513 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 17 294-299 |
| allfields_unstemmed |
10.21518/2079-701X-2021-17-294-299 doi (DE-627)DOAJ078833868 (DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff DE-627 ger DE-627 rakwb rus I. N. Zakharova verfasserin aut Hypercholesterolemia in children and adolescents: focus on the familial variant 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. hypercholesterolemia cascade screening universal screening targeted screening opportunistic screening lipid center Medicine R I. M. Osmanov verfasserin aut I. I. Pshenichnikova verfasserin aut T. M. Tvorogova verfasserin aut I. N. Kholodova verfasserin aut I. V. Berezhnaya verfasserin aut E. V. Skorobogatova verfasserin aut D. I. Kholodov verfasserin aut T. I. Bocharova verfasserin aut Yu. V. Koba verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2021), 17, Seite 294-299 (DE-627)1760607460 26585790 nnns year:2021 number:17 pages:294-299 https://doi.org/10.21518/2079-701X-2021-17-294-299 kostenfrei https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff kostenfrei https://www.med-sovet.pro/jour/article/view/6513 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 17 294-299 |
| allfieldsGer |
10.21518/2079-701X-2021-17-294-299 doi (DE-627)DOAJ078833868 (DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff DE-627 ger DE-627 rakwb rus I. N. Zakharova verfasserin aut Hypercholesterolemia in children and adolescents: focus on the familial variant 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. hypercholesterolemia cascade screening universal screening targeted screening opportunistic screening lipid center Medicine R I. M. Osmanov verfasserin aut I. I. Pshenichnikova verfasserin aut T. M. Tvorogova verfasserin aut I. N. Kholodova verfasserin aut I. V. Berezhnaya verfasserin aut E. V. Skorobogatova verfasserin aut D. I. Kholodov verfasserin aut T. I. Bocharova verfasserin aut Yu. V. Koba verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2021), 17, Seite 294-299 (DE-627)1760607460 26585790 nnns year:2021 number:17 pages:294-299 https://doi.org/10.21518/2079-701X-2021-17-294-299 kostenfrei https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff kostenfrei https://www.med-sovet.pro/jour/article/view/6513 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 17 294-299 |
| allfieldsSound |
10.21518/2079-701X-2021-17-294-299 doi (DE-627)DOAJ078833868 (DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff DE-627 ger DE-627 rakwb rus I. N. Zakharova verfasserin aut Hypercholesterolemia in children and adolescents: focus on the familial variant 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. hypercholesterolemia cascade screening universal screening targeted screening opportunistic screening lipid center Medicine R I. M. Osmanov verfasserin aut I. I. Pshenichnikova verfasserin aut T. M. Tvorogova verfasserin aut I. N. Kholodova verfasserin aut I. V. Berezhnaya verfasserin aut E. V. Skorobogatova verfasserin aut D. I. Kholodov verfasserin aut T. I. Bocharova verfasserin aut Yu. V. Koba verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2021), 17, Seite 294-299 (DE-627)1760607460 26585790 nnns year:2021 number:17 pages:294-299 https://doi.org/10.21518/2079-701X-2021-17-294-299 kostenfrei https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff kostenfrei https://www.med-sovet.pro/jour/article/view/6513 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 17 294-299 |
| language |
Russian |
| source |
In Медицинский совет (2021), 17, Seite 294-299 year:2021 number:17 pages:294-299 |
| sourceStr |
In Медицинский совет (2021), 17, Seite 294-299 year:2021 number:17 pages:294-299 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
hypercholesterolemia cascade screening universal screening targeted screening opportunistic screening lipid center Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Медицинский совет |
| authorswithroles_txt_mv |
I. N. Zakharova @@aut@@ I. M. Osmanov @@aut@@ I. I. Pshenichnikova @@aut@@ T. M. Tvorogova @@aut@@ I. N. Kholodova @@aut@@ I. V. Berezhnaya @@aut@@ E. V. Skorobogatova @@aut@@ D. I. Kholodov @@aut@@ T. I. Bocharova @@aut@@ Yu. V. Koba @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
1760607460 |
| id |
DOAJ078833868 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ078833868</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505014319.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21518/2079-701X-2021-17-294-299</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ078833868</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">I. N. Zakharova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypercholesterolemia in children and adolescents: focus on the familial variant</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypercholesterolemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cascade screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">universal screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">opportunistic screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lipid center</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. M. Osmanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Pshenichnikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. M. Tvorogova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. N. Kholodova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. V. Berezhnaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Skorobogatova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. I. Kholodov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. I. Bocharova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. V. Koba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинский совет</subfield><subfield code="d">Remedium Group LLC, 2019</subfield><subfield code="g">(2021), 17, Seite 294-299</subfield><subfield code="w">(DE-627)1760607460</subfield><subfield code="x">26585790</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">number:17</subfield><subfield code="g">pages:294-299</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21518/2079-701X-2021-17-294-299</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.med-sovet.pro/jour/article/view/6513</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-701X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5790</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="e">17</subfield><subfield code="h">294-299</subfield></datafield></record></collection>
|
| author |
I. N. Zakharova |
| spellingShingle |
I. N. Zakharova misc hypercholesterolemia misc cascade screening misc universal screening misc targeted screening misc opportunistic screening misc lipid center misc Medicine misc R Hypercholesterolemia in children and adolescents: focus on the familial variant |
| authorStr |
I. N. Zakharova |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760607460 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
26585790 |
| topic_title |
Hypercholesterolemia in children and adolescents: focus on the familial variant hypercholesterolemia cascade screening universal screening targeted screening opportunistic screening lipid center |
| topic |
misc hypercholesterolemia misc cascade screening misc universal screening misc targeted screening misc opportunistic screening misc lipid center misc Medicine misc R |
| topic_unstemmed |
misc hypercholesterolemia misc cascade screening misc universal screening misc targeted screening misc opportunistic screening misc lipid center misc Medicine misc R |
| topic_browse |
misc hypercholesterolemia misc cascade screening misc universal screening misc targeted screening misc opportunistic screening misc lipid center misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Медицинский совет |
| hierarchy_parent_id |
1760607460 |
| hierarchy_top_title |
Медицинский совет |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760607460 |
| title |
Hypercholesterolemia in children and adolescents: focus on the familial variant |
| ctrlnum |
(DE-627)DOAJ078833868 (DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff |
| title_full |
Hypercholesterolemia in children and adolescents: focus on the familial variant |
| author_sort |
I. N. Zakharova |
| journal |
Медицинский совет |
| journalStr |
Медицинский совет |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
294 |
| author_browse |
I. N. Zakharova I. M. Osmanov I. I. Pshenichnikova T. M. Tvorogova I. N. Kholodova I. V. Berezhnaya E. V. Skorobogatova D. I. Kholodov T. I. Bocharova Yu. V. Koba |
| format_se |
Elektronische Aufsätze |
| author-letter |
I. N. Zakharova |
| doi_str_mv |
10.21518/2079-701X-2021-17-294-299 |
| author2-role |
verfasserin |
| title_sort |
hypercholesterolemia in children and adolescents: focus on the familial variant |
| title_auth |
Hypercholesterolemia in children and adolescents: focus on the familial variant |
| abstract |
Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. |
| abstractGer |
Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. |
| abstract_unstemmed |
Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
17 |
| title_short |
Hypercholesterolemia in children and adolescents: focus on the familial variant |
| url |
https://doi.org/10.21518/2079-701X-2021-17-294-299 https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff https://www.med-sovet.pro/jour/article/view/6513 https://doaj.org/toc/2079-701X https://doaj.org/toc/2658-5790 |
| remote_bool |
true |
| author2 |
I. M. Osmanov I. I. Pshenichnikova T. M. Tvorogova I. N. Kholodova I. V. Berezhnaya E. V. Skorobogatova D. I. Kholodov T. I. Bocharova Yu. V. Koba |
| author2Str |
I. M. Osmanov I. I. Pshenichnikova T. M. Tvorogova I. N. Kholodova I. V. Berezhnaya E. V. Skorobogatova D. I. Kholodov T. I. Bocharova Yu. V. Koba |
| ppnlink |
1760607460 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.21518/2079-701X-2021-17-294-299 |
| up_date |
2024-07-03T20:08:31.373Z |
| _version_ |
1803589843816546304 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ078833868</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505014319.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2021 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21518/2079-701X-2021-17-294-299</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ078833868</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7a3f06c061a14747918fdaa6cd3f06ff</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">I. N. Zakharova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypercholesterolemia in children and adolescents: focus on the familial variant</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in childhood. With significant prevalence in the population, familial hypercholesterolemia is rarely diagnosed in time due to the Long absence of clinical manifestations. Today the urgent task is to develop and implement programs of primary detection of familial hypercholesterolemia in children and adolescents. Early detection of patients with familial hypercholesterolemia and timely initiation of adequate lipid-lowering therapy will curb the rate of atherosclerosis progression, which will significantly reduce disability and mortality from cardiovascular diseases in older age groups. There are four types of screening: cascade, targeted, opportunistic and universal. Cascade screening is currently considered the most effective and cost-effective way to identify new patients with familial hypercholesterolemia among relatives of an index patient, the patient with the established diagnosis. Targeted screening is based on searching for individuals with familial hypercholesterolemia among groups of patients with the early development of atherosclerotic vascular lesions, for example, in cardiology or neurology hospitals. Opportunistic screening is a non-systematic, sporadic determination of cholesterol levels in patients seeking medical care for any reason. It is most applicable in primary care health care settings. Universal screening is a mass screening of certain age groups and is a highly effective way of early diagnosis, especially in combination with reverse cascade screening of parents, siblings, and other relatives of the index patient. Implementation of programs of early childhood detection of familial hypercholesterolemia, setting up systems of adequate routing of patients, timely prescription of effective lipid-lowering therapy will contribute to health preservation and prolongation of working age, development, and preservation of labor potential of the country.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypercholesterolemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cascade screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">universal screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">opportunistic screening</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lipid center</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. M. Osmanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Pshenichnikova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. M. Tvorogova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. N. Kholodova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. V. Berezhnaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Skorobogatova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. I. Kholodov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. I. Bocharova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. V. Koba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинский совет</subfield><subfield code="d">Remedium Group LLC, 2019</subfield><subfield code="g">(2021), 17, Seite 294-299</subfield><subfield code="w">(DE-627)1760607460</subfield><subfield code="x">26585790</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">number:17</subfield><subfield code="g">pages:294-299</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21518/2079-701X-2021-17-294-299</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7a3f06c061a14747918fdaa6cd3f06ff</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.med-sovet.pro/jour/article/view/6513</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-701X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5790</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="e">17</subfield><subfield code="h">294-299</subfield></datafield></record></collection>
|
| score |
7.4024982 |